Fibromyalgia Clinical Trial
Official title:
A Pilot Study on the Combined Use of Cognitive Behavioral Therapy (CBT) and Milnacipran
Verified date | March 2011 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Fibromyalgia Syndrome (FMS) afflicts 2% of the U.S. population and have huge individual and
societal costs in terms of quality of life, social and work functioning, health care use,
and lost productivity. Although single therapy approaches such as medication, graduated
exercise, and Cognitive Behavioral Therapy (CBT) are well-established treatment approaches,
the majority of FMS continue to report significant levels of pain and pain-related
disability. Testing the efficacy of using combination therapies such and CBT with medication
has considerable potential to maximize treatment response. Also, exploring the biological
and psychological mechanisms underlying combination treatment may pave the way for
developing new treatments for FMS sufferers.
We chose to study drug and CBT for several reasons: 1) the scarcity of trials that
manipulate medications along with CBT in FMS, 2) the prohibitive nature of adding an
exercise treatment arm in a study that has both time and budgetary constraints, 3) the
complexity in understanding the mechanism of actions of 3 different modes of intervention in
one clinical trial, and 4) the desire to explore mechanisms in this program of research, in
particular the potential effects of a biological intervention (drug) on what is
traditionally considered a psychological outcome (pain-related attributions and cognition)
and the potential effects of a psychological intervention (CBT) on what is traditionally
considered a physiological outcome (pain sensitivity).
Status | Completed |
Enrollment | 48 |
Est. completion date | September 2012 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Must be between the ages of 18 to 65 years of age 2. Must have been diagnosed with fibromyalgia by a rheumatologist 3. Must have an overall body pain average score = 4 4. Must be on stable doses of your current medication for at least past four weeks 5. Must report all medication including herbal supplements and over-the-counter medications that you are currently taking to a member of the research team. 6. Must limit any changes in your medication(s)during the 21-week study time period unless medically necessary 7. Must be willing to maintain a medication diary provided to you during the 21-week study period 8. Must be willing to abstain (not take) any fibromyalgia related medication (including over-the-counter)for at least 6-hours prior to each of the three testing visits. (Otherwise, you may take these medication immediately after pain sensitivity testing has been completed and as prescribed in-between visits) 9. Must experience the symptoms of fibromyalgia syndrome (FMS) that decreases (limits) your ability to perform daily activities. Exclusions Criteria: 1. You have uncontrolled hypertension(high blood pressure) systolic >160 mm Hg or diastolic blood pressure > 100 mm Hg) 2. If you have a history of: heart disease, glaucoma, or hepatitis 3. You have been diagnosed with any type of peripheral neuropathy 4. You have a body mass index (BMI) of more than 34 5. You currently or frequently have thoughts of harming yourself or committing suicide. 6. You are in the process of filing, or plan to file for disability benefits within the study timeline. 7. You plan to undergo an elective surgery within the study timeline. 8. You have been diagnosed with another major rheumatic conditions (i.e. rheumatoid arthritis, systemic lupus erythematosus, scleroderma and other connective tissue diseases) 9. You are currently pregnant, are planning to become pregnant, or are breastfeeding 10. You have been diagnosed with schizophrenia or manic-depressive. 11. You are currently taking any of the following medications: 1. fluoxetine, Brand Names: Prozac, Prozac Weekly, Rapiflux, Sarafem 2. sertraline, Brand Name: Zoloft 3. paroxetine, Brand Names: Paxil, Paxil CR, Pexeva 4. citalopram, Brand Name: Celexa 5. escitalopram, Brand Names: Lexapro 6. venlafaxine, Brand Names: Effexor, Effexor XR 7. mirtazapine, Brand Names: Remeron, Remeron SolTab 8. duloxetine, Brand Name: Cymbalta NOTE: If you are taking any of the medication(s) listed above and are willing to discontinue its use for the duration of this study, you must first discuss your decision with your primary care physician (or prescribing doctor)regarding the appropriate regimen to wean off your current medication and receive his/her written consent before proceeding with enrollment. We will provide you a "Dear Doctor" letter that explains the study details. 12. If you are currently taking or have ever taken Savella® (milnacipran) 13. You are currently participating in other pain research study or have previously been enrolled in any study or class in which cognitive behavioral therapy or educational formats were used to help control pain or stress related to fibromyalgia 14. You are unwilling or unable to comply with the study guidelines Note: If you have ever experienced an adverse event while taking any type of antidepressant, please alert the research team, while it may not exclude you from participating in the study, it is important that we are aware of the incident in order to keep you safe. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Clinical Research Center for Pain, 250 University Blvd | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Indiana University | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary analysis: Specific Aim: To estimate effect sizes for each of the three treatment conditions on each of the four outcome measures (i.e., self-report pain severity and physical function, pain-related beliefs and coping and evoked pain sensitivity). | Baseline, Week 9, and Week 21clinic visits | No | |
Secondary | To test the success of blinding, we will ask all subjects to identify their treatment group and will use McNemar's test to assess the strength of agreement between true assignment and correct answers. | Baseline, Week 9, and Week 21 clinic visits | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05659862 -
Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT03042728 -
Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program
|
N/A | |
Recruiting |
NCT06097091 -
Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia
|
N/A | |
Recruiting |
NCT04554784 -
Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia
|
N/A | |
Completed |
NCT03300635 -
Metabolism, Muscle Function and Psychological Factors in Fibromyalgia
|
N/A | |
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT03227952 -
Sensory Stimulation in Fibromyalgia
|
N/A | |
Completed |
NCT03166995 -
Postural Exercises in Women With Fibromyalgia
|
N/A | |
Recruiting |
NCT06237595 -
Vagus Nerve Stimulation in Fibromyalgia
|
N/A | |
Completed |
NCT01888640 -
Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)
|
N/A | |
Completed |
NCT03641495 -
Pain Education and Therapeutic Exercise for Fibromyalgia
|
N/A | |
Recruiting |
NCT05581628 -
FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
|
||
Active, not recruiting |
NCT05128162 -
Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia
|
Phase 2 | |
Completed |
NCT04674878 -
Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia
|
N/A | |
Active, not recruiting |
NCT04084795 -
Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia
|
N/A | |
Completed |
NCT03129906 -
Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients
|
N/A | |
Completed |
NCT05058911 -
Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia
|
N/A | |
Recruiting |
NCT04571853 -
New Educational Tool for FM
|
N/A | |
Recruiting |
NCT04571528 -
Effectiveness of VIRTUAL FIBROWALK STUDY
|
N/A |